{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T04:06:02Z","timestamp":1787889962708,"version":"build-2784847793"},"reference-count":25,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T00:00:00Z","timestamp":1596758400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Chang Gung Memorial Hospital, Kaohsiung Medical Center, Taiwan","award":["CMRPG8F0661-2"],"award-info":[{"award-number":["CMRPG8F0661-2"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.bj.2020.08.004","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T12:40:10Z","timestamp":1597236010000},"page":"S126-S131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"S1","title":["The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan"],"prefix":"10.1016","volume":"44","author":[{"given":"Ming-Chao","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Hung","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Nan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing-Houng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwong-Ming","family":"Kee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chin","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsai-Ling","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9172-1967","authenticated-orcid":false,"given":"Tsung-Hui","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bj.2020.08.004_bib1","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2020.08.004_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/hep.26371","article-title":"New horizons in hepatitis C antiviral therapy with direct-acting antivirals","volume":"58","author":"Aghemo","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2020.08.004_bib3","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jhep.2011.01.011","article-title":"Hepatitis C virus resistance to protease inhibitors","volume":"55","author":"Halfon","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2020.08.004_bib4","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","article-title":"Resistance to direct antiviral agents in patients with hepatitis C virus infection","volume":"138","author":"Sarrazin","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bj.2020.08.004_bib5","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","article-title":"Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus","volume":"53","author":"Pawlotsky","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2020.08.004_bib6","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1002\/hep.24594","article-title":"Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in\u00a0vitro and in\u00a0vivo correlations","volume":"54","author":"Fridell","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2020.08.004_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.04226-14","article-title":"In\u00a0vitro and in\u00a0vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A","volume":"59","author":"Krishnan","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bj.2020.08.004_bib8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jhep.2011.12.029","article-title":"A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C","volume":"57","author":"Lawitz","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2020.08.004_bib9","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1128\/AAC.00556-10","article-title":"Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in\u00a0vitro replicon system","volume":"54","author":"Fridell","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bj.2020.08.004_bib10","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1111\/liv.13128","article-title":"All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study","volume":"36","author":"Kao","year":"2016","journal-title":"Liver Int"},{"key":"10.1016\/j.bj.2020.08.004_bib11","doi-asserted-by":"crossref","first-page":"48576","DOI":"10.1074\/jbc.M407787200","article-title":"The NS5A protein of hepatitis C virus is a zinc metalloprotein","volume":"279","author":"Tellinghuisen","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bj.2020.08.004_bib12","series-title":"Hepatitis C viruses: genomes and molecular biology","article-title":"HCV NS5A: a multifunctional regulator of cellular pathways and virus replication","volume":"Chapter 9","author":"He","year":"2006"},{"key":"10.1016\/j.bj.2020.08.004_bib13","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1002\/hep.27113","article-title":"Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection","volume":"59","author":"Kumada","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.bj.2020.08.004_bib14","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1007\/s00535-015-1106-8","article-title":"Significance of variants associated with resistance to NS5A inhibitors in Japanese patients with genotype 1b hepatitis C virus infection as evaluated using cycling-probe real-time PCR combined with direct sequencing","volume":"51","author":"Uchida","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bj.2020.08.004_bib15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/nature08960","article-title":"Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect","volume":"465","author":"Gao","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.bj.2020.08.004_bib16","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1038\/ajg.2013.205","article-title":"A translational study of resistance emergence using sequential direct-acting antiviral agents for hepatitis C using ultra-deep sequencing","volume":"108","author":"Abe","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bj.2020.08.004_bib17","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1136\/gutjnl-2012-302600","article-title":"Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice","volume":"62","author":"Shi","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.bj.2020.08.004_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jhep.2012.09.037","article-title":"Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options","volume":"58","author":"Suzuki","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.bj.2020.08.004_bib19","article-title":"Naturally occurring drug resistance associated variants to hepatitis C virus direct-acting antiviral agents in treatment-naive HCV genotype 1b-infected patients in China","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bj.2020.08.004_bib20","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.coviro.2013.06.014","article-title":"Antiviral activity and resistance of HCV NS5A replication complex inhibitors","volume":"3","author":"Gao","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.bj.2020.08.004_bib21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/20014091084227","article-title":"Gamma glutamyl transferase","volume":"38","author":"Whitfield","year":"2001","journal-title":"Crit Rev Clin Lab Sci"},{"key":"10.1016\/j.bj.2020.08.004_bib22","doi-asserted-by":"crossref","first-page":"E115","DOI":"10.1111\/hepr.12474","article-title":"Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy","volume":"45","author":"Itakura","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.bj.2020.08.004_bib23","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12985-017-0826-1","article-title":"Real-life prevalence of resistance-associated variants against non-structural protein 5A inhibitors and efficiency of Daclatasvir + Asunaprevir therapy in Korean patients with genotype 1b hepatitis C","volume":"14","author":"Yu","year":"2017","journal-title":"Virol J"},{"key":"10.1016\/j.bj.2020.08.004_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00535-015-1080-1","article-title":"The clinical features of patients with a Y93H variant of hepatitis C virus detected by a PCR invader assay","volume":"51","author":"Kan","year":"2016","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.bj.2020.08.004_bib25","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1177\/1060028017704857","article-title":"Hepatitis C virus resistance testing in genotype 1: the changing role in clinical utility","volume":"51","author":"Molino","year":"2017","journal-title":"Ann Pharmacother"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417020301384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417020301384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:10:31Z","timestamp":1762420231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417020301384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S2319417020301384"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2020.08.004","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The incidence of resistance-associated variants to NS5A in HCV subtypes 1a and 1b in Taiwan","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2020.08.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Chang Gung University. Publishing services by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}